Recombinant Viral B8R Biotinylated Protein, CF
R&D Systems, part of Bio-Techne | Catalog # BT8225
Key Product Details
Source
CHO
Accession #
Structure / Form
Noncovalently-linked homodimer, biotinylated via sugars
Conjugate
Biotin
Applications
Bioactivity
Product Specifications
Source
Chinese Hamster Ovary cell line, CHO-derived viral B8R protein
Lys18-Ser272, with a C-terminal 6-His tag
Lys18-Ser272, with a C-terminal 6-His tag
Purity
>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Endotoxin Level
<0.10 EU per 1 μg of the protein by the LAL method.
N-terminal Sequence Analysis
Lys18
Predicted Molecular Mass
30 kDa (unlabeled)
Activity
Measured by its ability to inhibit rhIFN-gamma mediated protection of HeLa human cervical epithelial carcinoma cells to viral lysis. Meager, A. (1987) in Lymphokines and Interferons, a Practical Approach. Clemens, M.J. et al. (eds): IRL Press. 129.
Th ED50 for this effect is 0.5-3 ng/mL.
Th ED50 for this effect is 0.5-3 ng/mL.
Scientific Data Images for Recombinant Viral B8R Biotinylated Protein, CF
Recombinant Viral B8R Biotinylated Protein Bioactivity
Both Biotinylated Recombinant Viral B8R (Catalog # BT8225) and unlabeled Recombinant Viral B8R (Catalog # 8225-BR) inhibits IFN-gamma-mediated protection of HeLa human cervical epithelial carcinoma cells to viral lysis. The ED50 for this effect is 0.5-3 ng/mL. The similarity in activity highlights that the biotinylated protein is fully functional.Formulation, Preparation and Storage
BT8225
Formulation | Lyophilized from a 0.2 μm filtered solution in PBS. |
Reconstitution |
Reconstitute at 250 μg/mL in PBS.
|
Shipping | The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below. |
Stability & Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Background: B8R
virally-induced B8R binds and sequesters endogenous IFN-gamma, thereby suppressing the host immune response and promoting viral immune evasion (5). While B8R is not required for viral replication, it contributes significantly to Vaccinia virus virulence and is frequently inactivated prior to Vaccinia use in vaccines (5-9). IFN-gamma peptide mimetics that activate IFN-gamma R1 but are not bound and sequestered by B8R have been developed for research and therapeutic use (10, 11).
References
- Alcami, A. and G.L. Smith (1995) J. Virol. 69:4633.
- Goebel, S.J. et al. (1990) Virology 179:247.
- Puehler, F. et al. (1998) Virology 248:231.
- Mossman, K. et al. (1995) Virology 208:762.
- Smith, G.L. et al. (2013) J. Gen. Virol. 94:2367.
- Symons, J.A. et al. (2002) J. Gen. Virol. 83:1953.
- Verardi, P.H. et al. (2001) J. Virol. 75:11.
- Denes, B. et al. (2006) J. Gene Med. 8:814.
- Dimier, J. et al. (2011) J. Virol. 85:5016.
- Ahmed, C.M. et al. (2007) J. Immunol. 178:4576.
- Ahmed, C.M. et al. (2005) J. Virol. 79:5632.
Long Name
Soluble Interferon alpha/beta Receptor B8
Entrez Gene IDs
3707661 (Viral)
Gene Symbol
B8R
UniProt
Additional B8R Products
Product Documents for Recombinant Viral B8R Biotinylated Protein, CF
Product Specific Notices for Recombinant Viral B8R Biotinylated Protein, CF
For research use only
Loading...
Loading...
Loading...